Direct interaction of TrkA/CD44v3 is essential for NGF-promoted aggressiveness of breast cancer cells.
Breast cancer
CD44v3
Metastasis
NGF
TrkA
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
28 Mar 2022
28 Mar 2022
Historique:
received:
19
11
2021
accepted:
03
03
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
5
4
2022
Statut:
epublish
Résumé
CD44 is a multifunctional membrane glycoprotein. Through its heparan sulfate chain, CD44 presents growth factors to their receptors. We have shown that CD44 and Tropomyosin kinase A (TrkA) form a complex following nerve growth factor (NGF) induction. Our study aimed to understand how CD44 and TrkA interact and the consequences of inhibiting this interaction regarding the pro-tumoral effect of NGF in breast cancer. After determining which CD44 isoforms (variants) are involved in forming the TrkA/CD44 complex using proximity ligation assays, we investigated the molecular determinants of this interaction. By molecular modeling, we isolated the amino acids involved and confirmed their involvement using mutations. A CD44v3 mimetic peptide was then synthesized to block the TrkA/CD44v3 interaction. The effects of this peptide on the growth, migration and invasion of xenografted triple-negative breast cancer cells were assessed. Finally, we investigated the correlations between the expression of the TrkA/CD44v3 complex in tumors and histo-pronostic parameters. We demonstrated that isoform v3 (CD44v3), but not v6, binds to TrkA in response to NGF stimulation. The final 10 amino acids of exon v3 and the TrkA H112 residue are necessary for the association of CD44v3 with TrkA. Functionally, the CD44v3 mimetic peptide impairs not only NGF-induced RhoA activation, clonogenicity, and migration/invasion of breast cancer cells in vitro but also tumor growth and metastasis in a xenograft mouse model. We also detected TrkA/CD44v3 only in cancerous cells, not in normal adjacent tissues. Collectively, our results suggest that blocking the CD44v3/TrkA interaction can be a new therapeutic option for triple-negative breast cancers.
Sections du résumé
BACKGROUND
BACKGROUND
CD44 is a multifunctional membrane glycoprotein. Through its heparan sulfate chain, CD44 presents growth factors to their receptors. We have shown that CD44 and Tropomyosin kinase A (TrkA) form a complex following nerve growth factor (NGF) induction. Our study aimed to understand how CD44 and TrkA interact and the consequences of inhibiting this interaction regarding the pro-tumoral effect of NGF in breast cancer.
METHODS
METHODS
After determining which CD44 isoforms (variants) are involved in forming the TrkA/CD44 complex using proximity ligation assays, we investigated the molecular determinants of this interaction. By molecular modeling, we isolated the amino acids involved and confirmed their involvement using mutations. A CD44v3 mimetic peptide was then synthesized to block the TrkA/CD44v3 interaction. The effects of this peptide on the growth, migration and invasion of xenografted triple-negative breast cancer cells were assessed. Finally, we investigated the correlations between the expression of the TrkA/CD44v3 complex in tumors and histo-pronostic parameters.
RESULTS
RESULTS
We demonstrated that isoform v3 (CD44v3), but not v6, binds to TrkA in response to NGF stimulation. The final 10 amino acids of exon v3 and the TrkA H112 residue are necessary for the association of CD44v3 with TrkA. Functionally, the CD44v3 mimetic peptide impairs not only NGF-induced RhoA activation, clonogenicity, and migration/invasion of breast cancer cells in vitro but also tumor growth and metastasis in a xenograft mouse model. We also detected TrkA/CD44v3 only in cancerous cells, not in normal adjacent tissues.
CONCLUSION
CONCLUSIONS
Collectively, our results suggest that blocking the CD44v3/TrkA interaction can be a new therapeutic option for triple-negative breast cancers.
Identifiants
pubmed: 35346305
doi: 10.1186/s13046-022-02314-4
pii: 10.1186/s13046-022-02314-4
pmc: PMC8962522
doi:
Substances chimiques
CD44V3,8-10
0
Hyaluronan Receptors
0
NTRK1 protein, human
0
Protein Isoforms
0
Nerve Growth Factor
9061-61-4
Receptor, trkA
EC 2.7.10.1
tropomyosin kinase
EC 2.7.11.28
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110Informations de copyright
© 2022. The Author(s).
Références
J Pers Med. 2021 Nov 16;11(11):
pubmed: 34834563
NPJ Precis Oncol. 2018 Feb 16;2(1):4
pubmed: 29872722
Oncogene. 2009 May 7;28(18):1960-70
pubmed: 19330021
Cell. 1991 Apr 5;65(1):13-24
pubmed: 1707342
J Hematol Oncol. 2018 May 10;11(1):64
pubmed: 29747682
J Biol Chem. 1997 Oct 31;272(44):27913-8
pubmed: 9346940
Nature. 1993 Jan 7;361(6407):79-82
pubmed: 7678446
J Cell Biol. 2017 Dec 4;216(12):4255-4270
pubmed: 29114068
Genes Dev. 2002 Dec 1;16(23):3074-86
pubmed: 12464636
Adv Pharm Bull. 2021 May;11(3):426-438
pubmed: 34513617
Cancer Discov. 2019 Jan;9(1):96-113
pubmed: 30361447
Adv Cancer Res. 2008;101:63-92
pubmed: 19055943
Lancet. 1995 Mar 11;345(8950):615-9
pubmed: 7534855
BMC Res Notes. 2008 Jul 29;1:57
pubmed: 18710510
Genes Dev. 1998 Apr 1;12(7):1058-71
pubmed: 9531542
Oncotarget. 2015;6(12):9807-19
pubmed: 25840418
Oncogene. 2018 Mar;37(11):1472-1484
pubmed: 29321661
Int J Biochem Cell Biol. 1998 Mar;30(3):299-305
pubmed: 9611772
Histopathology. 2005 Oct;47(4):420-8
pubmed: 16178897
Bioinformatics. 2018 Jan 15;34(2):294-296
pubmed: 29028877
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Int Med Res. 2015 Apr;43(2):173-9
pubmed: 25571897
Nucleic Acids Res. 2021 Jun 21;49(11):6213-6237
pubmed: 34086943
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nature. 2006 Apr 20;440(7087):1069-72
pubmed: 16547516
Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4563-8
pubmed: 23487783
Genes Dev. 2002 Feb 1;16(3):307-23
pubmed: 11825873
Cell Signal. 2014 Oct;26(10):2234-9
pubmed: 25025570
Neuron. 2007 Jan 4;53(1):25-38
pubmed: 17196528
Front Cell Dev Biol. 2021 Jun 29;9:676568
pubmed: 34268306
Chin J Cancer. 2017 Mar 29;36(1):36
pubmed: 28356139
Nat Protoc. 2017 Feb;12(2):255-278
pubmed: 28079879
J Cell Biol. 1995 Feb;128(4):687-98
pubmed: 7532176
Semin Cancer Biol. 2008 Aug;18(4):260-7
pubmed: 18467123
Curr Protoc Bioinformatics. 2019 Mar;65(1):e66
pubmed: 30489695